虽然自 Boros 和 Korenyi 首次报告急性巨核细胞白血病(AMeg-L)以来已有50余年,但由于原始巨核细胞缺乏特异性形态,因此对该病临床病理学特征的了解较肤浅。近年随着对巨核细胞超微细胞化学及免疫细胞化学的深入研究,对 AMeg-L 的认识逐渐丰富。FAB协作组在1985年已将本病列为急性髓系白血病M7型,这势必引起血液学界更广泛的注意。 Although more than 50 years have passed since Boros and Korenyi first reported acute megakaryocytic leukemia (AMeg-L), the understanding of the clinicopathological features of this disease is superficial because of the lack of specific morphology of the original megakaryocytic cells. In recent years, with the in-depth study of megakaryocyte chemotaxis and immunocytochemistry, the understanding of AMeg-L gradually enriched. FAB collaborative group in 1985 this disease has been classified as acute myeloid leukemia M7 type, which is bound to cause more widespread hematological attention.